GlaxoSmithKline will cut more than 30 drug development programmes and may sell its rare diseases unit, as the FTSE 100 group seeks to inject more “edge and pace” into its decision making, its new chief executive Emma Walmsley has said.
{iframe}https://www.ft.com/content/b511563a-71ee-11e7-93ff-99f383b09ff9{/iframe}